STATUS OF THE CLAIMS

1-15 (cancelled)

16. (Currently Amended) A method of protecting ocular neural tissue of a patient's eye from damage caused by a photodynamic therapy (PDT) treatment, the method comprising the steps of:
(a) administering a PDT treatment employing electromagnetic radiation at an intensity of from 150 to 900 mW/cm^2 to the eye of the patient, and;
(b) delivering a composition to said patient's ocular neural tissue, wherein the composition comprises an amount of brimonidine effective to protect a plurality of ocular neurons from cell death caused by a photoactive component of the PDT treatment, as compared to ocular neuron cell death observed in a patient who has received PDT in the absence of the administration of said amount of brimonidine.

17. (cancelled)

18. (previously presented) The method of claim 16 wherein said brimonidine is administered at a time sufficiently before said PDT treatment to permit localization within ocular tissue prior to said treatment.

19. (previously presented) The method of claim 16 wherein said brimonidine is administered intravenously.

20. (previously presented) The method of claim 16 wherein said brimonidine is administered through intraocular injection.

21. (previously presented) The method of claim 16 wherein said brimonidine is administered by subretinal injection.

22. (previously presented) The method of claim 16 wherein said brimonidine is administered by intravitreal injection.

23-29 (cancelled)

30. (previously presented) The method of any of the preceding claims 16 or 18-22 wherein said composition also comprises an therapeutically effective amount of a antiangiogenic compound.

31-38 (cancelled)

39. (Previously presented) The method of claim 16 wherein said PDT treatment occurs prior to the administration of brimonidine to said ocular neural tissue.

40. (Previously Presented) The method of claim 16 wherein said PDT treatment occurs following the administration of brimonidine to said ocular neural tissue.